Generation Investment Management LLP Purchases New Holdings in IDEXX Laboratories, Inc. $IDXX

Generation Investment Management LLP purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 567,322 shares of the company’s stock, valued at approximately $304,277,000. IDEXX Laboratories makes up about 1.9% of Generation Investment Management LLP’s portfolio, making the stock its 19th largest position. Generation Investment Management LLP owned about 0.71% of IDEXX Laboratories as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of IDXX. Mutual of America Capital Management LLC increased its holdings in shares of IDEXX Laboratories by 79.6% in the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $405,000. Plato Investment Management Ltd raised its position in shares of IDEXX Laboratories by 37.1% during the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after acquiring an additional 835 shares during the last quarter. Genesis Wealth Advisors LLC bought a new position in IDEXX Laboratories in the second quarter valued at about $215,000. Finally, ORG Wealth Partners LLC acquired a new stake in IDEXX Laboratories in the second quarter worth about $273,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the sale, the executive vice president directly owned 11,287 shares in the company, valued at approximately $7,336,098.52. This trade represents a 3.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $708.45 on Monday. The stock has a market cap of $56.57 billion, a P/E ratio of 58.99, a P/E/G ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $735.00. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a fifty day simple moving average of $645.28 and a 200 day simple moving average of $580.40.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company posted $2.80 earnings per share. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Jefferies Financial Group restated a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Finally, UBS Group increased their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $730.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.